觸媒製藥 CPRX 深 滬
已收盤 10-10 16:00:00 美东时间
20.36
-0.460
-2.21%
華盛通- 最 高20.99
- 今 開20.99
- 成交量 127.36万股
- 最 低 20.26
- 昨 收 20.82
- 總市值 24.84亿
- 52周最高 26.58
- 市盈率 靜 15.52
- 換手率 1.04%
- 52周最低 19.05
- 委 比 -40.04%
- 總股本 1.22亿
- 歷史最高 26.58
- 量 比 1.06
- 振 幅 3.51%
- 歷史最低 0.37
- 每 手 1
- 風險率 1.51%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Catalyst Pharmaceuticals Announces Presentations at Upcoming Scientific Conferences
Catalyst Pharmaceuticals announced that data developed by the company will be presented at upcoming scientific conferences, including the Child Neurology Society (CNS) Annual Meeting and the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting. The presentations focus on glucocorticoid use in Duchenne muscular dystrophy, patient characteristics in Lambert Eaton myasthenic syndrome, and other rare disease resea...
10-09 12:03
Catalyst Pharmaceuticals announces $200M share repurchase program through 2026
Catalyst Pharmaceuticals (NASDAQ:CPRX) has authorized a new share repurchase program of up to $200M. The program allows for the repurchase of outstanding common stock between October 1, 2025, and Dece...
10-01 20:31
Catalyst Pharmaceuticals Announces $200 Million Share Repurchase Program
Pharmaceutical company Catalyst Pharmaceuticals announced a $200 million share repurchase program through December 31, 2026, funded by its strong cash reserves of over $650 million as of June 2025. CEO Richard Daly highlighted the company's solid financial health and commitment to delivering value to shareholders while maintaining its strategic growth focus in rare disease treatments. Repurchases may occur via open market or private transactions,...
10-01 12:03
Capricor Therapeutics Responds to FDA Posting of Complete Response Letter (CRL) for Deramiocel
Capricor Therapeutics issued a statement regarding the U.S. FDA's public posting of its Complete Response Letter (CRL) for the Biologics License Application (BLA) for Deramiocel, its investigational cell therapy for treating cardiomyopathy associated with Duchenne muscular dystrophy (DMD). The company was not notified in advance of the posting but acknowledges the FDA's decision. Capricor plans to make its preliminary response to the CRL availabl...
09-09 13:20
Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences
Catalyst Pharmaceuticals announced that its CEO and management team will participate in four upcoming investor conferences between September 3 and September 9, 2025. The events include the Wells Fargo Healthcare Conference, Cantor Global Healthcare Conference, H.C. Wainwright Global Investment Conference, and Baird Global Conference. Each session will feature presentations available via webcast links on the company's Investors page, with replays ...
08-28 12:03
Catalyst Pharma Settles Patent Dispute with Lupin
Catalyst Pharma ( ($CPRX) ) has shared an announcement. On August 25, 2025, Cat...
08-26 05:04
Catalyst Pharmaceuticals Reaches Settlement With Lupin To Delay Generic FIRDAPSE Launch Until 2035
Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare
08-25 20:06
Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Lupin Pharmaceuticals
Catalyst Pharmaceuticals and its licensor SERB have settled patent litigation with Lupin Ltd and Lupin Pharmaceuticals, Inc., resolving a dispute over Lupin's application to market a generic version of FIRDAPSE. Under the terms of the settlement, Lupin is prohibited from marketing its generic FIRDAPSE in the U.S. before February 25, 2035, unless specific provisions in the agreement are triggered. The agreement also terminates all ongoing patent l...
08-25 12:03
Capricor Therapeutics Announces First Subjects Dosed in Phase 1 Clinical Trial of Novel Exosome-Based Vaccine
Capricor Therapeutics has initiated a Phase 1 clinical trial of its StealthX™ exosome-based vaccine, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the U.S. Department of Health and Human Services’ Project NextGen. The trial, which marks a key milestone in vaccine development, aims to evaluate the vaccine's safety and immunogenicity, offering an alternative to mRNA vaccines through a natural delivery system usin...
08-18 13:00
Capricor Therapeutics Announces Type A Meeting Scheduled with U.S. FDA
<p>Capricor Therapeutics has postponed its Q2 2025 financial results release to August 11, 2025, due to a scheduled FDA meeting about its Deramiocel therapy for DMD-associated cardiomyopathy. A webcast and conference call will review financials and provide updates at 4:30 p.m. ET on August 11.</p>
08-08 12:30
